FGF23 and systemic lupus erythematosus: In this regard, a study focused primarily on bone turnover in 72 SLE patients and 10 age- and sex-matched healthy individuals revealed significantly higher serum levels of FGF23 in patients treated with glucocorticoids than in those not taking them [16].